Novartis | NVS - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 41.64B 458M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Bausch Health Companies USD 4.54B 14M 2026-06
Biogen USD 3.92B 918.2M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Canopy Growth CAD 158.44M 60.15M 2026-03
Corcept Therapeutics USD 153.8M 4.62M 2026-06
Drreddys Laboratories INR 167.57B 165.8B 2026-03
Eli Lilly USD 47.74B 11.11B 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
J&J USD 54.9B 2.82B 2026-06
Merck USD 27.73B 786M 2026-06
Novartis USD 31.75B 374M 2026-06
Novartis USD 31.37B 4.1B 2026-03
Pacira USD 122.01M 13.22M 2026-06
Perrigo USD 1.05B 57.2M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Phibro Animal Health USD 316.47M 34.6M 2026-06
Prestige Brands USD 153.81M 32.88M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
Sanofi EUR 30.01B 1.66B 2026-03
Supernus Pharmaceuticals USD 347.38M 26.55M 2026-06
Zoetis USD 2.06B 8M 2026-06